Research Article| Volume 31, ISSUE 2, P328-335, February 2009

Download started.


Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers

      This paper is only available as a PDF. To read, Please Download here.


      Background: Fampridine (4-aminopyridine) is a potassium channel blocker that has been evaluated as a treatment for patients with spinal cord injury and multiple sclerosis.
      Objective: The purpose of this study was to determine the pharmacokinetics of a single dose of an orally administered solution of 14C-labeled fampridine in healthy volunteers.
      Methods: In this open-label, single-dose study conducted in an inpatient setting, healthy adult men were administered an oral solution containing 15 mg of 14C-labeled fampridine (100 μCi) in a fasted state. In addition to blood sampling for analysis of plasma 14C-radioactivity at prescribed intervals over 7 days, all urine and feces were collected for analysis of drug recovery and disposition. Urine samples were also analyzed for metabolic profiling. Plasma pharmacokinetic parameters of the 14C-radiolabeled drug were determined using standard liquid-scintillation techniques. Recovery was calculated to provide the total amount of radioactivity excreted as a proportion of the original dose. Nonhydrolyzed and hydrolyzed urine extracts were analyzed for radioactivity and metabolites using reverse-phase, isocratic high-performance liquid chromatography with spectrophotometric and radioactive detection. Tolerability was assessed through evaluation of vital signs, hematologic and other laboratory parameters, and electrocardiography.
      Results: The 4 white male subjects had a mean (SD) age of 21 (2) years. No clinically significant abnormalities in vital signs, clinical chemistry, hematology, urinalysis, or electrocardiography were observed either before or during the study. Peak plasma radioactivity was reached at 1 hour after dosing, with a median concentration of 72.9 ng · mL−1. There was complete disappearance of radioactivity by 24 hours (limit of quantitation, 400 disintegrations/min per peak), and the calculated median t1/2 was 3.14 hours. Total cumulative recovery of 14C-radioactivity was 96.36%, with only 0.51% of drug recovered in feces. On chromatography, 2 metabolites accounted for a low proportion of total urinary radioactivity (3% and 6% of total radioactivity in the interval from 0 to 4 hours after dosing; 17% and 9% in the interval from 8 to 12 hours after dosing). Three subjects reported mild and transient dizziness occurring 1 half-hour after dosing; this was considered possibly related to the study drug.
      Conclusion: Fampridine administered as an oral solution was rapidly absorbed and was nearly completely and rapidly eliminated as unchanged drug via urinary excretion, suggesting that it is unlikely to undergo substantial metabolic transformation.

      Key words:

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gold MS
        • Shuster MJ
        • Levine JD
        Characterization of six voltage-gated K+ currents in adult rat sensory neurons.
        J Neurophysiol. 1996; 75: 2629-2646
        • Coetzee WA
        • Amarillo Y
        • Chiu J
        • et al.
        Molecular diversity of K+ channels.
        Ann N Y Acad Sci. 1999; 868: 233-285
        • Bowman WC
        • Savage AO
        Pharmacological actions of aminopyridines and related compounds.
        Rev Pure Appl Pharmacol Sci. 1981; 2: 317-371
        • Sherratt RM
        • Bostock H
        • Sears TA
        Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres.
        Nature. 1980; 283: 570-572
        • Targ EF
        • Kocsis JD
        4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve.
        Brain Res. 1985; 328: 358-361
        • Blight AR
        Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury.
        Brain Res Bull. 1989; 22: 47-52
        • Shi R
        • Blight AR
        Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord.
        Neuroscience. 1997; 77: 553-562
        • Lundh H
        Effects of 4-aminopyridine on neuromuscular transmission.
        Brain Res. 1978; 153: 307-318
        • Kim YI
        • Goldner MM
        • Sanders DB
        Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission.
        Muscle Nerve. 1980; 3: 105-111
        • Smith KJ
        • Felts PA
        • John GR
        Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.
        Brain. 2000; 123: 171-184
        • Lundh H
        • Nilsson O
        • Rosén I
        Effects of 4-aminopyridine in myasthenia gravis.
        J Neurol Neurosurg Psychiatry. 1979; 42: 171-175
        • Lundh H
        • Nilsson O
        • Rosén I
        4-Aminopyridine—a new drug tested in the treatment of Eaton-Lambert syndrome.
        J Neurol Neurosurg Psychiatry. 1977; 40: 1109-1112
        • Agoston S
        • van Weerden T
        • Westra P
        • Broekert A
        Effects of 4-aminopyridine in Eaton Lambert Syndrome.
        Br J Anaesth. 1978; 50: 383-385
        • Strupp M
        • Kalla R
        • Dichgans M
        • et al.
        Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
        Neurology. 2004; 62: 1623-1625
        • Glasauer S
        • Kalla R
        • Büttner U
        • et al.
        4-Aminopyridine restores visual ocular motor function in upbeat nystagmus.
        J Neurol Neurosurg Psychiatry. 2005; 76: 451-453
        • Kalla R
        • Glasauer S
        • Büttner U
        • et al.
        4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
        Brain. 2007; 130: 2441-2451
        • Hansebout RR
        • Blight AR
        • Fawcett S
        • Reddy K
        4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients.
        J Neurotrauma. 1993; 10: 1-18
        • Potter PJ
        • Hayes KC
        • Hsieh JT
        • et al.
        Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases.
        Spinal Cord. 1998; 36: 147-155
        • Segal JL
        • Pathak MS
        • Hernandez JP
        • et al.
        Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial.
        Pharmacotherapy. 1999; 19: 713-723
        • van der Bruggen MA
        • Huisman HB
        • Beckerman H
        • et al.
        Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.
        J Neurol. 2001; 248: 665-671
        • Cardenas DD
        • Ditunno J
        • Graziani V
        • et al.
        Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
        Spinal Cord. 2007; 45: 158-168
        • Stefoski D
        • Davis FA
        • Faut M
        • Schauf CL
        4-Aminopyridine improves clinical signs in multiple sclerosis.
        Ann Neurol. 1987; 21: 71-77
        • Davis FA
        • Stefoski D
        • Rush J
        Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
        Ann Neurol. 1990; 27: 186-192
        • Bever Jr, CT
        • Young D
        • Anderson PA
        • et al.
        The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
        Neurology. 1994; 44: 1054-1059
        • Polman CH
        • Bertelsmann FW
        • van Loenen AC
        • Koetsier JC
        4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
        Arch Neurol. 1994; 51: 292-296
        • Schwid SR
        • Petrie MD
        • McDermott MP
        • et al.
        Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
        Neurology. 1997; 48: 817-821
        • Goodman AD
        • Cohen JA
        • Cross A
        • et al.
        Fampridine-SR in multiple sclerosis: A randomized, doubleblind, placebo-controlled, doseranging study.
        Mult Scler. 2007; 13: 357-368
        • Goodman AD
        • Brown TR
        • Cohen JA
        • et al.
        • for the Fampridine MSF202 Study Group
        Dose comparison trial of sustained-release fampridine in multiple sclerosis.
        Neurology. 2008; 71: 1134-1141
        • Goodman AD
        • Brown TR
        • Krupp L
        • et al.
        Sustained release of oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial.
        Lancet. 2009 (In press)
        • Evenhuis J
        • Agoston S
        • Salt PJ
        • et al.
        Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation.
        Br J Anaesth. 1981; 53: 567-570
        • Uges DR
        • Sohn YJ
        • Greijdanus B
        • et al.
        4-Aminopyridine kinetics.
        Clin Pharmacol Ther. 1982; 31: 587-593
        • Van Diemen HA
        • Polman CH
        • Koetsier JC
        • et al.
        4-Aminopyridine in patients with multiple sclerosis: Dosage and serum level related to efficacy and safety.
        Clin Neuropharmacol. 1993; 16: 195-204
        • Hayes KC
        • Katz MA
        • Devane JG
        • et al.
        Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
        J Clin Pharmacol. 2003; 43: 379-385
        • Ritschel WA
        Handbook of Basic Pharmacokinetics—Including Clinical Applications. 4th ed. Drug Intelligence Publications, Hamilton, Ill1992
        • Glantz SA
        Primer of Biostatistics. McGraw-Hill, New York, NY1981